Canadian Owned and Operated
Drugs don’t affect everyone in the same way. Some do not work as well as expected (low efficacy) and some result in toxicity and death. Fortunately, we can predict many efficacy and adverse effect problems through genomic testing and performing a pharmacogenetic analysis. Using this type of screen, the BioAro team can perform a risk analysis of a medications a treatment that is commonly prescribed for a condition you may have. A patient’s DNA sequence can help in the following aspects of prescribing:
Finding the right medication or treatment may take several attempts before finding one that works. With pharmacogenetics the chances that the first medication used is the best choice is much higher.
Clinical trials are designed with a set of participation parameters. When conducting a clinical trial for a new drug to treat a certain health condition, the participants will be selected based on their medical history and symptoms. However, one key piece of screening is missing… their genetic profile.
Importantly, our DNA can impact our reaction and uptake of different drugs, so it is entirely possible to unknowingly set-up a clinical trial that is doomed from the beginning, due to your recruitment process. By recruiting only those that genetically match the drug that is being tested, the drug can enter market and start being used much faster, saving time, money, and research. This could increase the number of medication options available and would have built in parameters for who will benefit the most from that treatment.
Booking: you will follow the same process as the genetic analysis options. If more information is required beyond the intake form you will also receive a 15 minute consultation with a member of our team to collect detailed information on your medical and medication history.